©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Methodol. Dec 26, 2015; 5(4): 212-215
Published online Dec 26, 2015. doi: 10.5662/wjm.v5.i4.212
Published online Dec 26, 2015. doi: 10.5662/wjm.v5.i4.212
Monitoring anticoagulant therapy with new oral agents
Allan Ramos-Esquivel, Department of Pharmacology, School of Medicine, University of Costa Rica, San José 11501-2060, Costa Rica
Author contributions: The author solely contributed to this paper.
Conflict-of-interest statement: There are not any conflicts of interest to disclose.
Correspondence to: Allan Ramos-Esquivel, MD, MSc, Department of Pharmacology, School of Medicine, University of Costa Rica, Sede Rodrigo Facio, San Pedro Calle 27, San José 11501-2060, Costa Rica. allanramoscr@gmail.com
Telephone: +506-8844-8187 Fax: +506-2237-3930
Received: June 28, 2015
Peer-review started: July 5, 2015
First decision: July 28, 2015
Revised: September 22, 2015
Accepted: October 12, 2015
Article in press: October 13, 2015
Published online: December 26, 2015
Processing time: 169 Days and 21 Hours
Peer-review started: July 5, 2015
First decision: July 28, 2015
Revised: September 22, 2015
Accepted: October 12, 2015
Article in press: October 13, 2015
Published online: December 26, 2015
Processing time: 169 Days and 21 Hours
Core Tip
Core tip: New oral anticoagulants are replacing oral vitamin K antagonists for some practical advantages, like unnecessary monitoring and a better pharmacokinetic profile. Nevertheless, in some circumstances, their anticoagulant activity must be monitored in order to prevent adverse outcomes. In this minireview a list of the available laboratory test are reviewed to better understand the pros and cons of each analysis.